Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0 A new treatment for people with multiple myeloma will now be available on the NHS in England. Daratumumab (Darzalex) was approved by the National Institute of Health and Care Excellence (NICE) in combination with two other drugs, bortezomib (Velcade) […]Continue Reading ...
Israeli scientists and physicians develop a new technology for profiling the unique genetic makeup of myeloma tumor cells that will allow better diagnosis and treatment Cancer arises when cells lose control. Deciphering the “blueprint” of cancer cells – outlining how cancer cells hijack specific pathways for uncontrolled proliferation – will lead to more efficient ways […]Continue Reading ...
NEWTON, Mass., Sept. 13, 2018 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that updated clinical data from the Phase 2b STORM (Selinexor Treatment of Refractory Myeloma) study evaluating selinexor, the Company’s lead, oral Selective Inhibitor of Nuclear Export (SINE) compound, in heavily pretreated patients with penta-refractory multiple myeloma, were […]Continue Reading ...
NEWTON, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) — Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical data from the Phase 2b STORM study evaluating the Company’s lead, oral Selective Inhibitor of Nuclear Export (SINE) compound selinexor in heavily pretreated patients with refractory multiple myeloma, has been selected for oral presentation at […]Continue Reading ...
May 15, 2018 Multiple myeloma is the second most common type of blood cancer in the United States, impacting more than 25,000 people each year and disproportionatly affecting African-American men. While patients have access to more quality treatment therapies than ever before, the disease is still regarded as an incurable condition that often leads to […]Continue Reading ...
April 26, 2018 A study in today’s issue of JAMA Oncology reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead to the blood cancer multiple myeloma. The study was conducted by researchers at Albert Einstein College […]Continue Reading ...
April 20, 2018 The diagnosis and treatment of multiple myeloma, a cancer affecting plasma cells, traditionally forces patients to suffer through a painful bone biopsy. During that procedure, doctors insert a bone-biopsy needle through an incision to get a bone marrow sample -; or make a larger incision and remove a section of bone via […]Continue Reading ...
Just about two months after the FDA paused two medical trials of pembrolizumab (Keytruda) mixture treatments in more than one myeloma, the company has issued a follow-up caution about protection considerations. The PD-1 blocker is not licensed for more than one myeloma, and it additionally should not be utilized in mixture with different immunomodulators like […]Continue Reading ...
Researchers at Mayo Clinic have identified three specific gene types that account for a known two-to-three-fold increase in myeloma diagnoses among African-Americans. Researchers also demonstrated the ability to study race and racial admixture more accurately using DNA analysis. The findings were published today in Blood Cancer Journal. “Myeloma is a serious blood cancer that occurs […]Continue Reading ...
A $2 million phase 2 Small Business Technology Transfer (STTR) grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma has been awarded to a Medical University of South Carolina (MUSC) startup company, Leukogene Therapeutics, Inc., in collaboration with MUSC researcher and company founder, Nathan G. Dolloff, […]Continue Reading ...
July 28, 2018 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended broadening the existing marketing authorization for Darzalex® (daratumumab) for use as frontline (initial) therapy. The recommendation is for the use of daratumumab in combination […]Continue Reading ...
May 11, 2018 In a 10-patient cohort study led by Dr. Jean Roy (hematologist and professor at the Faculty of Medicine of Université de Montréal) that aims to understand how to mitigate the risks associated with the treatment of multiple myeloma, a malignant cancer, researchers have adopted an innovative approach based on the unique immunological […]Continue Reading ...
April 27, 2018 Bone marrow biopsies are the gold standard for diagnosing and monitoring the progression of multiple myeloma, but these procedures are far too invasive to perform at every patient visit. Scientists from the Dana-Farber Cancer Institute and the Broad Institute of MIT and Harvard, however, have shown that two ways to measure multiple […]Continue Reading ...
March 27, 2018 Multiple myeloma is a rare incurable disease that is diagnosed in more than 30,000 people each year in the United States. Only half of patients with multiple myeloma are expected to survive five years after their diagnosis. Moffitt Cancer Center researchers are trying to identify patients who are at a higher risk […]Continue Reading ...
June 29, 2017 An Australian-led analysis crew has demonstrated a brand new healing means that may re-build and give a boost to bone, providing hope for people with the debilitating bone most cancers, more than one myeloma. The findings have been revealed these days within the scientific magazine Blood, and have been introduced at a […]Continue Reading ...
- New nanotechnology approach shows promise in treating triple negative breast cancer
- Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
- Maternal deaths following C-section 50 times higher in Africa compared to high-income countries
- Apple watch could detect irregular heart beat says study
- Queen Mary University of London’s BCI boosts radionuclide imaging capabilities with MILabs VECTor technology
- Girls should be encouraged to gain more ball skills, shows study
- Acute doses of synthetic cannabinoid can impair critical thinking and memory
- Presence of bacteria in urine does not always point to infection, shows study
- Scientists identify a new role for nerve-supporting cells
- Hidden differences between pathology of CTE and Alzheimer’s disease discovered
- Knowing causative genes of osteoporosis may open door to more effective treatments
- Toilet-seat based cardiovascular monitoring system getting ready to begin commercialization
- New model for intensive care identifies factors that send ill patients to ICU
- Recommendations Issued for HSCT in Multiple Myeloma
- Deep brain stimulation provides sustained relief for severe depression
- “Statistical significance” may soon be a thing of past?
- Researchers track effects of epigenetic marks carried by sperm chromosomes
- AHA News: Family Adopts Three Children With Three Different Heart Conditions
- Research into opioid painkillers could provide clues for safer drug development
- Lung cancer survivor recounts her lifetime struggles